Phase 4CompletedAge-related condition
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
- Sponsor
- Astellas Pharma Global Development, Inc. (Industry)
- Enrollment
- 888 enrolled
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Mirabegron; Placebo
- Ages
- older adults
- Registry
- NCT02216214
Full record on ClinicalTrials.gov
From the registry
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
Primary outcomes
- Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 Hours
- Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 Hours
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered
Papers citing this trial
- Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
Drugs & aging
- Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
BMC geriatrics